Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Modine Manufacturing Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Modine Manufacturing Company trades at $229.33 (market cap $12.17B). The key difference: Modine Manufacturing Company is far larger — about 2.7× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | MOD | |
|---|---|---|
Market Cap | $4.49B | $12.17B |
Sector | Health | Technology |
52-Week High | $28.06 | $306.89 |
52-Week Low | $20.06 | $90.02 |
Enterprise Value | $3.69B | $12.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Modine (MOD) trades at $235.19, up 1.83% on the day, amid a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58B in 2025, with net income of $184M, though 2026 projections show margin compression. Analyst consensus remains strongly bullish with a $328.80 price target, driven by optimism around its data center cooling business, which is expected to grow 60-80% in FY27 according to Seeking Alpha (2026-06-11).
The outlook is mixed: robust growth in data center demand offers significant upside, but high valuations (P/E 104.07) and near-term technical weakness pose risks. Investors face volatility from supply chain challenges and competitive pressures in the HVAC segment, though institutional support and consistent earnings outperformance provide a foundation for long-term growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
